What You Should Know:
- Senseonics Holdings, Inc. and Ascensia Diabetes Care announced that the FDA has cleared the Eversense® 365 CGM system.
- This marks a significant advancement in diabetes management, offering a fully-implantable, long-term continuous glucose monitoring (CGM) solution for individuals with Type 1 and Type 2 diabetes aged 18 and older.
Eversense 365: Uninterrupted Living with Diabetes
Eversense 365 is set to transform the lives of people with diabetes by
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
Abbott Launches OTC Continuous Glucose Monitor, Lingo
What You Should Know:
- Abbott, a global healthcare company, has announced the U.S. availability of Lingo, a continuous glucose monitoring (CGM) system designed for individuals who want to improve their overall health and wellness.
- Lingo is the first CGM available without a prescription designed for individuals who want to improve their overall health and wellness, regardless of whether they have diabetes.
A Powerful Tool for Health Management
Lingo combines a biosensor
Read More
DexCom Launches Non-Prescription Glucose Biosensor in U.S.
What You Should Know:
- Millions of Americans with Type 2 diabetes and prediabetes now have a new option for managing their glucose levels.
- DexCom, a leader in continuous glucose monitoring (CGM) technology announced the launch of Stelo, the first over-the-counter (OTC) glucose biosensor available in the US.
What is Stelo?
Stelo is a small, wearable sensor that provides real-time glucose readings directly to a smartphone app. Unlike traditional blood glucose meters,
Read More
Abbott and Medtronic Partner to Integrate CGM System & Insulin Delivery Devices
What You Should Know:
- Abbott and Medtronic announced a groundbreaking partnership to develop an integrated continuous glucose monitoring (CGM) system designed to seamlessly work with Medtronic’s automated insulin delivery (AID) and smart insulin pen systems.
- The strategic collaboration aims to improve diabetes management by enabling more precise insulin dosing and reducing the burden on patients.
CGM System and Insulin Delivery Devices Integration
The new CGM sensor,
Read More
Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable
What You Should Know:
- A large majority of physicians feel GLP-1s are being overprescribed, according to a new survey from Virta Health, a leader in type 2 diabetes reversal.
- The Virta Health survey was conducted in partnership with Beresford Research and included 300 primary care providers, endocrinologists, and obesity specialists across the United States sheds light on the medical community's views on the rapidly growing class of GLP-1 medications, often hailed as
Read More
American Kidney Fund Taps AI Partner to Speed Early Diagnosis of Kidney Diseases
What You Should Know:
- Ubie, a global healthcare AI platform, and the American Kidney Fund (AKF), a leading kidney disease non-profit, have joined forces to improve early detection of kidney disease.
- This strategic collaboration aims to leverage Ubie's AI-powered Symptom Checker and AKF's expertise to empower patients and accelerate diagnosis.
Why Early Diagnosis Matters
Kidney disease is a major health concern, affecting millions in the US. Chronic kidney disease
Read More
Abbott Unveils FreeStyle Libre 3 Plus: World’s Smallest CGM Sensor with Future AID Compatibility
What You Should Know:
- At the American Diabetes Association conference, Abbott unveiled a new addition to its FreeStyle Libre portfolio – the FreeStyle Libre 3 Plus sensor.
- The sensor boasts the distinction of being the world's smallest, thinnest, and most discreet continuous glucose monitoring (CGM) sensor available.
Unmatched Design and Performance
The FreeStyle Libre 3 Plus sensor offers a unique combination of user-centric features:
Unmatched Discreetness: The
Read More
Teladoc Health’s AI Scores Big in Diabetes Management: Personalized Nudges and Coaching Boost Patient Engagement and Outcomes
What You Should Know:
- Teladoc Health (NYSE:TDOC), a leader in virtual healthcare, presented compelling new data at the American Diabetes Association's 84th Scientific Sessions. The findings showcase the effectiveness of Teladoc Health's AI-powered approach to managing type 2 diabetes.
- The study focused on the impact of personalized health nudges on patients identified as at-risk for uncontrolled diabetes through mobile devices
AI-Driven Nudges Lead to Improved Blood Sugar
Read More
What Will It Take to Achieve Value From Digitally Enabled Diabetes Care?
A report from the Peterson Health Technology Institute (PHTI) found that many digital diabetes management platforms aren’t providing meaningful ROI for patients or the health system as a whole. Users of common technologies only see small, incremental clinical benefits, such as 0.23%–0.60% point reduction in HbA1c when compared to traditional care. Meanwhile, some health plans and employers are actually seeing an increase in overall costs as spending on these platforms can often
Read More
CCS Unveils AI Predictive Model to Predict & Improves CGM Adherence in Diabetes Management
What You Should Know:
- CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced PropheSee™ a new, AI-powered predictive model for healthcare organizations focused on improving adherence in the population of people that have been prescribed a continuous glucose monitoring (CGM) device to help manage their
Read More
